A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.
Video content above is prompted by the following:
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL
July 30th 2025Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.
Read More
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More